Holen Sie sich die Stockscreener-App
1.205
0.41%
-0.015
Schlusskurs vom Vortag:
$1.22
Offen:
$1.23
24-Stunden-Volumen:
291.14K
Relative Volume:
0.27
Marktkapitalisierung:
$92.67M
Einnahmen:
$4.72B
Nettoeinkommen (Verlust:
$-123.85M
KGV:
-0.0843
EPS:
-14.2981
Netto-Cashflow:
$-303.12M
1W Leistung:
-7.25%
1M Leistung:
-62.27%
6M Leistung:
-49.79%
1J Leistung:
-82.02%
1-Tages-Spanne:
$1.17
$1.23
1-Wochen-Bereich:
$1.09
$1.31
52-Wochen-Spanne:
$0.9337
$4.6887
Accendra Health Inc Stock (ACH) Company Profile
Firmenname
Accendra Health Inc
Sektor
Branche
Telefon
(804) 277-4304
Adresse
4435 WATERFRONT DRIVE, GLEN ALLEN
Compare ACH vs MCK, COR, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACH
Accendra Health Inc
|
1.205 | 100.75M | 4.72B | -123.85M | -303.12M | -14.30 |
MCK
Mckesson Corp
|
889.11 | 97.79B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
323.16 | 60.05B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
235.30 | 53.13B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
91.24 | 9.86B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
0.97 | 873.84M | 14.85M | -136.07M | 7.25M | -0.4726 |
Accendra Health Inc Stock (ACH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Herabstufung | UBS | Buy → Neutral |
| 2024-07-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-13 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-04-26 | Fortgesetzt | Citigroup | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-30 | Fortgesetzt | JP Morgan | Underweight |
| 2022-03-23 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2021-04-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-17 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-25 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-07-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-07-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-05-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-01-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-01-07 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-15 | Hochstufung | CLSA | Underperform → Outperform |
| 2019-09-06 | Bestätigt | BofA/Merrill | Neutral |
| 2019-04-10 | Bestätigt | BofA/Merrill | Neutral |
| 2019-04-03 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-01 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-01-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-15 | Hochstufung | CLSA | Underperform → Outperform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2018-12-12 | Herabstufung | Goldman | Buy → Neutral |
| 2018-09-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-11 | Herabstufung | CLSA | Outperform → Sell |
| 2018-04-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-26 | Hochstufung | Goldman | Sell → Neutral |
| 2017-11-02 | Herabstufung | HSBC Securities | Buy → Hold |
| 2016-03-24 | Hochstufung | Goldman | Sell → Neutral |
| 2015-12-07 | Herabstufung | Goldman | Neutral → Sell |
| 2015-08-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2012-08-01 | Eingeleitet | HSBC Securities | Underweight |
| 2009-08-05 | Hochstufung | Citigroup | Sell → Buy |
| 2008-12-01 | Herabstufung | HSBC Securities | Neutral → Underweight |
Alle ansehen
Accendra Health Inc Aktie (ACH) Neueste Nachrichten
Accendra (ACH) Quarterly Figures: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Stock Move: The Stock Gains 5.61% for the Current SessionBasic EPS Analysis - vinanet.vn
Accendra Health Inc (NYSE: ACH) Share Price, ACH Stock News, ACH Share Price & Updates - Kalkine
Accendra Health scraps equity program, expects CEO successor By Investing.com - Investing.com South Africa
Accendra Health Inc (ACH) (Q2 2026) Earnings Call Highlights: Na - GuruFocus
Accendra Health provides update on CEO transition, credit facility - HME News
symbol__ Stock Quote Price and Forecast - CNN
Accendra Health Drops Equity Issuance Plan, Targets September CEO Announcement - citybiz
Accendra Health drops equity issuance plan as CEO succession process advances - Yahoo Finance
Accendra Health scraps equity program, expects CEO successor - Investing.com
Form 8K Accendra Health Inc For: 17 August By Investing.com - Investing.com Nigeria
Accendra Health sells first of two non-core assets, expects about $45 million cash injection - Bitget
Accendra Health to forgo ATM program, sees ~$45M from two asset sales; CEO successor expected by mid-September - TradingView
Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans - Yahoo Finance
Accendra Health ready to put weak Q2 in rear view - HME News
Accendra Health (ACH) Drops 9% to $1.10 as Selling Pressure PersistsAnchored VWAP - vinanet.vn
Accendra Health 2Q Loss/Shr $1.16 >ACH - Moomoo
Accendra Health (NYSE:ACH) Rating Lowered to "Hold" at Robert W. Baird - MarketBeat
Dimensional Fund Advisors LP Buys Shares of 2,606,620 Accendra Health, Inc. $ACH - MarketBeat
Accendra Health, Inc. (ACH) stock price, news, quote and history - Yahoo Finance UK
Baird downgrades Accendra Health stock rating on weak results By Investing.com - Investing.com South Africa
Accendra Health, Inc. (ACH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Accendra Health adopts tax asset preservation plan - HME News
Accendra Health's Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search - marketscreener.com
Citigroup Downgrades Accendra Health to Neutral From Buy, Adjusts PT to $1.50 From $4.50 - marketscreener.com
Baird Downgrades Accendra Health to Neutral From Outperform, Adjusts PT to $1.50 From $6 - marketscreener.com
ACCENDRA HEALTH INC : BAIRD CUTS TO NEUTRAL RATING; CUTS TARGET PRICE TO $1.5 FROM $6 - Bitget
Baird downgrades Accendra Health stock rating on weak results - Investing.com
Accendra Health Chief Executive Edward Pesicka to Retire - Moomoo
Accendra Health tumbles 25% on Q2 miss and weak guidance By Investing.com - Investing.com UK
Accendra Health, Inc. (ACH) Stock Forecasts - Yahoo Finance
Accendra Health Reports 111.1% Wider Q2 2026 Loss at -$0.19/Share - AlphaStreet
Accendra Health Releases Q2 2026 Financial Results - AlphaStreet
Accendra Health’s Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search - StreetInsider
Accendra Health says Q2 2026 results miss forecast on weaker revenue growth, slower collections recovery - Bitget
Accendra Health, Inc. Updates Earnings Guidance for the Full Year 2026 - marketscreener.com
Accendra Health seeks next president, CEO - HME News
ACCENDRA HEALTH 2026: Revenue $613.23M, EPS ($1.16) — 10-Q Summary - TradingView
Accendra Health (NYSE: ACH) Q2 loss deepens amid revenue drop and debt swap - Stock Titan
Accendra Health CEO to retire by end of the year - Virginia Business
Earnings call transcript: Accendra Health cuts 2026 outlook as shares sink in Q2 2026 - Investing.com
Accendra Health tumbles 25% on Q2 miss and weak guidance - Investing.com
Accendra Health, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:ACH) 2026-08-10 - Seeking Alpha
Accendra Health (ACH) Q2 2026 Earnings Call Transcript - The Globe and Mail
Accendra Health's Ed Pesicka Announces Intent to Retire; Board o - GuruFocus
Edward A. Pesicka Plans to Retire as Chief Executive Officer of Accendra Health, Inc - marketscreener.com
Is Accendra Health Inc (ACH) Undervalued After Q2 Earnings Miss? EPS: -$1.16, Revenue: $613.2M; GF Score: 52/100 - GuruFocus
Accendra Health CEO Edward Pesicka to retire by end of 2026 - Investing.com Nigeria
Accendra Health CEO Ed Pesicka Plans Retirement as Board Begins Successor Search - citybiz
Finanzdaten der Accendra Health Inc-Aktie (ACH)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):